Intervention Review

Tocilizumab for rheumatoid arthritis

  1. Jasvinder A Singh1,*,
  2. Saba Beg2,
  3. Maria Angeles Lopez-Olivo3

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 7 JUL 2010

Assessed as up-to-date: 31 MAR 2010

DOI: 10.1002/14651858.CD008331.pub2

How to Cite

Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2010, Issue 7. Art. No.: CD008331. DOI: 10.1002/14651858.CD008331.pub2.

Author Information

  1. 1

    Birmingham VA Medical Center, Department of Medicine, Birmingham, USA

  2. 2

    Minneapolis VA Medical Center and University of Minnesota, Medicine, Minneapolis, MN, USA

  3. 3

    The University of Texas, M.D. Anderson Cancer Center, General Internal Medicine, Ambulatory Treatment and Emergency Care, Houston, Texas, USA

*Jasvinder A Singh, Department of Medicine, Birmingham VA Medical Center, Faculty Office Tower 805B, 510 20th Street South, Birmingham, AL 35294, USA.

Publication History

  1. Publication Status: New
  2. Published Online: 7 JUL 2010


Cited in:


This article has been cited by:

  1. 1
    Petra Baji, Márta Péntek, László Czirják, Zoltán Szekanecz, György Nagy, László Gulácsi, Valentin Brodszky, Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison, The European Journal of Health Economics, 2014, 15, S1, 53